Table 2

Response rates vs. age in Phase 2 studies of 142 patients with CD33 positive AML in first relapse treated with gemtuzumab ozogamicin

Type of remission201/202/203 (n = 142)<60 yr (n = 62)≥60 yr (n = 80)
CR
 No. (%) of patients23 (16)11/62 (18)12/80 (15)
 95% CIsa(11, 23)(9, 30)(8, 25)
CRp
 No. (%) of patients19 (13)10/62 (16)9/80 (11)
 95% CIs(8, 20)(8, 28)(5, 20)
OR (CR + CRp)
 No. (%) of patients42 (30)21/62 (34)21/80 (26)
 95% CIs(22, 38)(22, 47)(17, 37)
  • a CI, confidence interval.